The Bio Report

The rise of antibiotic resistance and the threat of emerging viral pathogens have created global public health threats. Recce Pharmaceuticals is developing a new class of synthetic anti-infectives that it says can overcome the hyper-cellular mutation of bacteria and viruses. What’s more, the company says their potency doesn’t diminish even with repeated use. We spoke to James Graham, CEO of Recce, about its synthetic anti-infectives, how they work, and why they can be used repeatedly against a broad range of bacteria and viruses.